Jan 22, 2020 - Strapped with debt and battling legal controversies right and left, Teva’s best days could very well be behind it.
Jan 22, 2020 - Teva is set to hold the $10 support line.Company's restructuring and debt reduction on schedule.Future growth in place with two products leading it.
Jan 23, 2020 - Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
Jan 28, 2020 - Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
Feb 03, 2020 - Regulators are trying their best to help encourage competition, particularly in the biosimilars market.
Feb 05, 2020 - Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $12.10, moving +0.33% from the previous trading session.
Feb 07, 2020 - Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.
Feb 11, 2020 -
Teva Pharmaceutical Indus (NYSE: TEVA) announces its next round of earnings this Wednesday, February 12. Here is Benzinga's everything-that-matters guide for the Q4 earnings announcement.
Feb 12, 2020 - AIM ImmunoTech (NYSEMKT:AIM) +20% on discussing the potential role of Ampligen for use against the Wuhan 2019 Novel Coronavirus.TransEnterix (NYSEMKT:TRXC) +19% on CE Mark for pediatric use of Senhanc
Feb 12, 2020 - TEVA earnings call for the period ending December 31, 2019.